Denali Therapeutics Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing therapies for neurodegenerative and lysosomal storage diseases. This unaudited report covers the three months ended March 31, 2024, compared with Q1 2023. Denali has no approved products and reported no product revenue.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 or prior date |
|---|---|---|
| Collaboration revenue | $0 | $35.1 million |
| Research and development expense | $107.0 million | $128.8 million |
| General and administrative expense | $25.2 million | $27.1 million |
| Gain on divestiture | $14.5 million | — |
| Operating loss | $117.7 million | $120.8 million |
| Interest and other income, net | $15.9 million | $11.0 million |
| Net loss | $101.8 million; $0.68 per share | $109.8 million; $0.80 per share |
| Net cash used in operating activities | $113.6 million | $58.8 million |
| Cash, cash equivalents and marketable securities | $1.43 billion | $1.03 billion at Dec. 31, 2023 |
| Total assets / total liabilities | $1.58 billion / $125.6 million | $1.15 billion / $123.0 million at Dec. 31, 2023 |
Current assets were $973.6 million versus current liabilities of $82.6 million. The filing reports no conventional borrowings; operating lease liabilities totaled $50.5 million. No gross or operating margin is provided, and margins are not meaningful given zero collaboration revenue in Q1 2024. Cash, cash equivalents and restricted cash declined by $66.5 million during the quarter. Management believes available cash and investments can fund projected operations through at least 12 months after filing, subject to assumptions.
Material changes versus prior comparable period
- Collaboration revenue fell by $35.1 million, principally because Q1 2023 included $25.0 million from Sanofi and $10.0 million from Takeda milestone payments.
- R&D expense declined $21.8 million, largely because Q1 2023 included a $30.0 million F-star contingent consideration charge. Q1 2024 spending increased for eIF2B and ETV:SGSH programs, among other changes.
- Net loss narrowed by $8.0 million. Higher interest income and the divestiture gain partly offset the loss of collaboration revenue.
- Operating cash use increased $54.8 million year over year; investing cash use was $453.2 million, reflecting purchases of marketable securities net of maturities and sales.
- February’s private placement generated $499.3 million net proceeds. It included 3.2 million common shares and pre-funded warrants for 26.0 million shares, exercisable at $0.01 per share. The warrants were outstanding at quarter-end; reported weighted-average shares included a portion of them.
Outlook, commentary, risks and unusual items
- Management expects significant losses and expenses to continue, with R&D expense expected to increase as programs advance. Denali anticipates needing substantial additional funding over the longer term; additional capital is not assured.
- Denali plans to initiate a global Phase 2a BIIB122/DNL151 study in 2024, with up to $75.0 million in third-party research funding. The $12.5 million received in January was recorded as a liability and is expected to reduce R&D expense as qualifying study costs are incurred. After full funding, the funder may receive low-single-digit royalties on applicable worldwide sales.
- For tividenofusp alfa (DNL310) in Hunter syndrome, the company reported positive ongoing-study data and said the Phase 2/3 COMPASS study was enrolling, with completion expected in 2024. Following discussions with the FDA division, Denali said it believed an accelerated approval path may be open for discussion; this is not an approval or confirmed regulatory pathway.
- The Phase 2 HIMALAYA study of SAR443820/DNL788 in ALS did not meet its primary endpoint. Sanofi is evaluating the candidate in a separate Phase 2 MS study, which Denali said was fully enrolled.
- Part B of the TAK-594/DNL593 Phase 1/2 FTD-GRN study was voluntarily paused for protocol modifications and was expected to resume later in 2024. DNL126 dosing began in a Phase 1/2 MPS IIIA study; biomarker and safety data were expected by year-end 2024. These are stated expectations, not reported outcomes.
- Denali divested selected preclinical small-molecule assets on March 1 for a $15.0 million SAFE, recognized as a noncash gain of $14.5 million. The company may also receive up to approximately $1.2 billion in milestone payments, in cash or equity at the buyer’s election, plus potential royalties; these amounts are contingent, not guaranteed.
- Commitments included $33.1 million of non-cancellable Lonza manufacturing purchase commitments and $34.5 million under other clinical and manufacturing agreements. The new Salt Lake City lease had not commenced and was not recorded as a lease liability; Denali disclosed delays in the site build-out. The new lease’s undiscounted payments were estimated at $13.4 million.
- Principal risks include clinical and regulatory failure or delay, dependence on collaborators and contract manufacturers, manufacturing scale-up and facility delays, patent and other intellectual property challenges, need for future financing, and competitive, market, cybersecurity, privacy and geopolitical risks. Management reported effective disclosure controls and no material adverse legal proceedings known to it.
Most important facts for investors to verify
- Clinical progress and data quality for DNL310, DNL126, BIIB122/DNL151 and other programs; verify actual trial enrollment, readouts and regulatory feedback against company expectations.
- Implications of the failed ALS HIMALAYA primary endpoint for the RIPK1 program, and the status and results of the separate MS study.
- Cash burn, investment balances and the assumptions behind management’s stated 12-month-plus funding runway, including the timing of the $75.0 million study funding.
- Potential dilution from the 26.0 million pre-funded warrants and any subsequent warrant exercises or equity issuance.
- Terms, valuation and realization of the $15.0 million SAFE, as well as the contingent nature of the divestiture milestones and royalties.
- Execution and funding of manufacturing commitments, including the Salt Lake City facility build-out and Lonza obligations.